Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.73 |
| ▸ | CTSS | P25774 | 14/20 | 0.73 |
| ▸ | CTSB | P07858 | 11/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898712 | 1.00 | CTSK (0.73) | CTSKCTSSCTSBCTSLADAM10 | |
| SCHEMBL4895669 | 1.00 | CTSK (0.73) | CTSKCTSSCTSBCTSLADAM10 | |
| SCHEMBL4898805 | 0.89 | CTSK (0.70) | CTSKCTSSCTSBCTSLADAM10 | |
| SCHEMBL4889472 | 0.87 | CTSK (0.77) | CTSKCTSSCTSBADAM10ERBB2 | |
| SCHEMBL4897875 | 0.87 | CTSK (0.64) | CTSKCTSSCTSBCTSL | |
| SCHEMBL4897335 | 0.85 | CTSK (1.00) | CTSKCTSSCTSBKCNH2 | |
| Pexantel SCHEMBL5698680 | 0.83 | CTSS (0.53) | CTSKCTSSKDM4ETDP1 | |
| SCHEMBL4898169 | 0.83 | CTSS (0.61) | CTSKCTSSKDM4E | |
| SCHEMBL4898191 | 0.83 | CTSS (0.61) | CTSKCTSSKDM4E | |
| SCHEMBL4898182 | 0.83 | CTSS (0.61) | CTSKCTSSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234274-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | claimed |
| EP-1532124-B1 | Use of nitrile derivatives as medicament. | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | claimed |
| US-20050245522-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| US-20080234274-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1532124-B1 | Use of nitrile derivatives as medicament. | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050245522-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234274-A1 | Novel Compounds | CTSS, CTSB, CTSF | CTSK 8/4885CTSS 1/4885CTSB 2/4885 |
| US-20050245522-A1 | Novel compounds | CTSS, CTSB, CTSF | CTSK 8/4885CTSS 1/4885CTSB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.